

In re Application of: Francesca LEVI-SCHAFFER et al
Serial No.: 10/594,926
Filed: April 30, 2008
Office Action Mailing Date: September 22, 2011

Examiner: Nora Maureen ROONEY
Group Art Unit: 1644
Attorney Docket: **32379**
Confirmation No.: 5770

In the Claims:

- 1-41. (Cancelled)
42. (Currently amended) A bi-specific antibody comprising:
(i) a first target recognition component which specifically binds to the inhibitory receptor IRp60; and
(ii) a second target recognition component which specifically binds to a marker ~~specific for a mast cell, an eosinophil and/or a basophil, said marker being selected from the group consisting of IgE, cKIT, CCR3, IL-5R and FcεR1.~~
43. (Currently amended) The bi-specific antibody of claim 42, wherein a binding of said antibody to any one of a mast cell, an eosinophil and/or a basophil said cell inhibits allergic-type reactions.
44. (Previously Presented) The bi-specific antibody of claim 42, wherein said first and second target recognition components are linked via any one of a cross-linker, a linker compound, a carrier, a synthetic spacer, an immobilizing substrate and a (Gly₄Ser)₃ motif based flexible region.
45. (Previously Presented) The bi-specific antibody of claim 42, wherein said first and second target recognition components are cross-linked.
46. (Cancelled)
47. (Previously Presented) The bi-specific antibody of claim 42, wherein said recognition component is selected from any one of a naturally occurring, synthetic or recombinant antibody, single chain Fv (scFv), bi-functional scFv, diabody, F(ab) unit, F(ab') unit, bi-specific F(ab') conjugate, chemically

In re Application of: Francesca LEVI-SCHAFFER et al
Serial No.: 10/594,926
Filed: April 30, 2008
Office Action Mailing Date: September 22, 2011

Examiner: Nora Maureen ROONEY
Group Art Unit: 1644
Attorney Docket: 32379
Confirmation No.: 5770

cross-linked bi-functional antibody, linear antibody or a F(ab')2 antigen binding fragment of an antibody.

48. (Previously Presented) The bi-specific antibody of claim 42, wherein said recognition component is a F(ab') unit.

49. (Cancelled)

50. (Previously Presented) A pharmaceutical composition comprising as an active agent the bi-specific antibody of claim 42.

51. (Previously Presented) The pharmaceutical composition of claim 50, further comprising buffers, additives, stabilizers, diluents and/or excipients.

52. (Currently Amended) A method of treating an allergy, the method comprising administering to a subject in need thereof a therapeutically effective amount of a bi-specific antibody comprising:

(i) a first target recognition component which specifically binds to the inhibitory receptor IRp60; and
(ii) a second target recognition component which specifically binds to a marker ~~specific for a mast cell, an eosinophil and/or a basophil, said marker being selected from the group consisting of IgE, cKIT and CCR3;~~ thereby treating the allergy.

53-55. (Canceled)